Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important

Multiple Sclerosis

Volumn 23, Issue 2, 2017, Pages 182-184

  Wingerchuk, Dean M ^a   Weinshenker, Brian G ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY;

CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EDITORIAL; HUMAN; LABORATORY TEST; MYELOOPTIC NEUROPATHY; SENSITIVITY AND SPECIFICITY;

EID: 85011860359     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516688352     Document Type: Editorial

References (12)

1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
2. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 810-815.
4. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
5. Hamid SHM, Elsone L, Mutch K, et al. The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. Mult Scler. Epub ahead of print 23 2016. DOI: 10.1177/1352458516663853.
6. Hyun JW, Jeong IH, Joung A, et al. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology 2016; 86: 1772-1779.
7. Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria. Arthritis Care Res 2015; 67: 891-897.
8. Zekeridou A, Lennon VA,. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm 2015; 2 (4): e110.
9. Sepúlveda M, Armangué T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 2016; 3: e225.
10. Jurynczyk M, Weinshenker B, Akman-Demir G, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol 2016; 263: 140-149.
11. Kaneko K, Sato D, Nakashima I, et al. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry 2016; 87: 1257-1259.
12. Popescu BF, Guo Y, Jentoft ME, et al. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology 2015; 84: 148-158.